Is Phathom Pharmaceuticals, Inc. (PHAT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 25.2% / 30% | 15.5% / 30% | 9.3% / 30% | 4.02% / 5% | ✓ HALAL |
| DJIM | 25.2% / 33% | 15.5% / 33% | 9.3% / 33% | 4.02% / 5% | ✓ HALAL |
| MSCI | 81.7% / 33% | 50.2% / 33% | 30.1% / 33% | 4.02% / 5% | ✗ NOT HALAL |
| S&P | 25.2% / 33% | 15.5% / 33% | 9.3% / 33% | 4.02% / 5% | ✓ HALAL |
| FTSE | 81.7% / 33% | 50.2% / 33% | 30.1% / 50% | 4.02% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 87.1% | |
| Operating Margin | -10.3% | |
| Net Margin | -126.3% | |
| Return on Assets (ROA) | -31.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$167M |
| Free Cash Flow | -$167M |
| Total Debt | $212M |
| Current Ratio | 1.7 |
| Total Assets | $259M |
Price & Trading
| Last Close | $10.79 |
| 50-Day MA | $12.14 |
| 200-Day MA | $12.27 |
| Avg Volume | 1.1M |
| Beta | 0.6 |
|
52-Week Range
$2.21
| |
About Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Purification Calculator
As a halal stock with 4.02% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Phathom Pharmaceuticals, Inc. (PHAT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Phathom Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Phathom Pharmaceuticals, Inc.'s debt ratio?
Phathom Pharmaceuticals, Inc.'s debt ratio is 25.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 81.7%.
Does Phathom Pharmaceuticals, Inc. require dividend purification?
Yes, Phathom Pharmaceuticals, Inc. has an impermissible income ratio of 4.02%, which means 4.02% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Phathom Pharmaceuticals, Inc.'s key financial metrics?
Phathom Pharmaceuticals, Inc. has a market capitalization of $834M, and revenue of $175M. The company maintains a gross margin of 87.1% and a net margin of -126.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.